Zydus Cadila had earlier in October 2020 received approval to market the Fingolimod capsules in the strength of .5mg
Zydus Cadila had earlier in October 2020 received approval to market the Fingolimod capsules in the strength of .5mg
File photo

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Fingolimod capsules, used in the treatment of multiple sclerosis, in the American market.

The company has received tentative approval from the US Food and Drug Administration (USFDA) to market the product in the strength of .25 mg, Zydus Cadila said in a statement.

Earlier, in October 2020, the Ahmedabad-based group had received approval to market the Fingolimod capsules in the strength of .5mg.

Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

The drug will be manufactured at the Zydus's manufacturing facility at the SEZ, Ahmedabad.

The group now has 319 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal

www.freepressjournal.in